- |||||||||| depatuxizumab (ABT-806) / AbbVie, Life Science Pharma, Erbitux (cetuximab) / Eli Lilly, EMD Serono
High affinity chimeric antigen receptors with cross reactivity to clinically relevant EGFR mutated proteins (Virtual Meeting II: E-Posters) - Jun 11, 2020 - Abstract #AACRII2020AACR-II_5701; Broad specificity of EGFR806 CART cells to Amplified EGFR, EGFRvIII and EGFR-ECD mutants gives us the potential to clear various forms of EGFR. The enhanced anti-tumor efficacy by KIR based CAR in vivo setting provides us with additional therapeutic options for GBM.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical: The median OS was 9.3 months with encorafenib plus cetuximab with binimetinib, 9.3 months with the encorafenib plus cetuximab, and 5.9 months with the control regimen in patients with BRAF V600E–mutant metastatic CRC. @skopetz @MDAndersonNews #crcsm https://t.co/WHEtTCS5HH (Twitter) - Jun 11, 2020
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical, P3 data, Journal: Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. (Pubmed Central) - Jun 8, 2020 P3 In the safety lead-in, the safety and tolerability of the encorafenib, binimetinib, and cetuximab regimen is manageable and acceptable for initiation of the randomized portion of the study. The observed efficacy is promising compared with available therapies and, if confirmed in the randomized portion of the trial, could establish this regimen as a new standard of care for previously treated BRAF V600E-mutant mCRC.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, PD(L)-1 Biomarker, IO Biomarker: Current Understanding of Urachal Adenocarcinoma and Management Strategy. (Pubmed Central) - Jun 8, 2020 Surgery is the gold standard for localized disease, while different chemotherapy schemes have been used in metastatic setting. Novel findings based on mutational analysis of the tumor include the use of biological treatment, such as cetuximab, and immunotherapy, such as atezolizumab, with satisfactory responses, suggesting that personalized treatment could be the most suitable option for UC.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Tumor priming by SMO inhibition enhances antibody delivery and efficacy in a pancreatic ductal adenocarcinoma model. (Pubmed Central) - Jun 4, 2020 Sequencing the sHH inhibitor with cetuximab administration resulted in marked tumor growth inhibition compared to cetuximab alone. These studies suggest that PDAC drug delivery barriers confound efforts to employ mAb against targets in PDAC, and that short-term, intermittent exposure to stromal modulators can increase tumor cell exposure to therapeutic antibodies, improving their efficacy, and potentially minimize adverse effects that may accompany longer-term, continuous sHHI treatment.
- |||||||||| Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial completion date, Trial primary completion date: PD 0332991 and Cetuximab in Patients With Incurable SCCHN (clinicaltrials.gov) - May 31, 2020 P1/2, N=96, Active, not recruiting, Altogether, this work emphasizes the importance of the tumor microenvironment and considering the potential unintended consequences of therapeutically targeting cancer-driving proteins on non-tumorigenic cell types. Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Apr 2025 | Trial primary completion date: Jun 2020 --> Sep 2020
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Scott Kopetz, MD, PhD, on Colorectal Cancer: Encorafenib Plus Cetuximab With or Without Binimetinib https://t.co/P7rnbmH5PE #crcsm #oncology #cancer #ASCO20 @skopetz @MDAndersonNews (Twitter) - May 30, 2020
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Review, Journal, MSi-H Biomarker, IO Biomarker: Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. (Pubmed Central) - May 30, 2020 Here we review the clinical trials that specifically enrolled patients with BRAF-mutated CRC, from the phase I/II studies to the phase III trial BEACON CRC. We also examine the future directions towards a molecularly guided therapy for patients with BRAF-mutated CRC and the crucial role of a molecularly and clinically based algorithm in order to offer the best choice of treatment for these patients.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical, Retrospective data: Updated overall survival analysis from BEACON trial, via Dr @skopetz: no difference in median OS (both 9.3 months) for encorafenib/binimetinib/cetuximab vs encorafenib + cetuximab without bini (post-hoc analysis). ORR 27% vs 20%. #ASCO20 (Twitter) - May 29, 2020
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2/3 data, Journal: Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216. (Pubmed Central) - May 29, 2020 On the contrary, a high toxicity and mortality rate was detected in both arms, which underscores the vulnerability of patients with R/M SCCHN, and research on the need for further optimisation of the front-line chemotherapy backbone is ongoing. Overall, the proposed randomized II/III design has desirable properties that offer cost effectiveness, operational efficiency, and, most importantly, scientific innovation that can be considered for similar clinical research settings.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, P3 data, Journal, Monotherapy: Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040). (Pubmed Central) - May 29, 2020 One of the striking discrepancies between CheckMate 141 and KEYNOTE 040 was the OS observed in the control SOC arms (6.9 months median in KEYNOTE 040 versus 5.1 months in CheckMate 141), which inadvertently set a higher threshold in the bio-statistical analysis of KEYNOTE 040 so that the clinical outcome of every patient was influential in the analysis. We perform a comparative analysis of the two studies to identify potential factors in the control arm that can impact clinical trial bio-statistical outcomes and which may have implications for future immunotherapy clinical trial designs.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Adjuvant Anti-angiogenic Therapy Enhances Chemotherapeutic Uptake in a Murine Model of Head and Neck Cancer. (Pubmed Central) - May 27, 2020 The 20mg/kg anti-VEGFR3 + 5mg/kg anti-VEGFR2 and 30mg/kg anti-VEGFR3 + 2.5mg/kg anti-VEGFR2 significantly (p < 0.0004) improved percent-injected cetuximab-IRDye800CW dose/gram tumor tissue compared to other groups. Adjuvant, dual anti-angiogenic therapy targeting VEGFR2 and VEGFR3 significantly enhances tumor chemotherapeutic uptake compared to control.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Adverse events: Growth suppression of human oral cancer cells by candidate agents for cetuximab-side effects. (Pubmed Central) - May 27, 2020 It is noteworthy that, in addition to not interfering with the effect of cetuximab by both compounds, flavagline has additive effect for OSCC growth inhibition in vivo. Collectively, our results indicate that combination of cetuximab and these potential therapeutic agents for cetuximab-related toxicities could be a promising therapeutic strategy for patients with OSCC.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Differential escape mechanisms in cetuximab-resistant head and neck cancer cells. (Pubmed Central) - May 27, 2020 However, both of the resistant lines demonstrated increased phospho-serine 727 and total STAT3 expression compared to the parental lines. STAT3 knockdown promoted increased cytotoxicity both in the presence and absence of cetuximab in the resistant lines suggesting that STAT3 may be a common target in cetuximab resistance.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Dual-targeting of EGFR and Neuropilin-1 Attenuates Resistance to EGFR-targeted Antibody Therapy in KRAS-mutant Non-Small Cell Lung Cancer. (Pubmed Central) - May 27, 2020 Importantly, we demonstrate that the EGFR/NRP1 dual-targeting bispecific antibody, Ctx-TPP11, attenuates the downstream signaling driven by the ternary complex via the cellular co-internalization and degradation of the NRP1-coupled complex, resulting in the alleviation of cetuximab resistance in KRAS NSCLCs in vitro and in vivo, including patient-derived xenograft mouse models. Our study shows that the dual-targeting of EGFR and NRP1 with a bispecific antibody might be an effective therapeutic strategy for KRAS NSCLC.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer. (Pubmed Central) - May 25, 2020 We developed a novel targeted therapy and radiation sensitizer for non-small cell lung cancer (NSCLC) based on cetuximab conjugated nanoparticle that targets epidermal growth factor receptor (EGFR) and delivers small interfering RNA (siRNA) against polo-like kinase 1 (PLK1)...Our findings demonstrate that C-siPLK1-NP is effective as a targeted therapy and as a potent radiation sensitizer for NSCLC. Potential application to other EGFR+ cancer types such as colorectal and breast cancer is also demonstrated.
- |||||||||| Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO Biomarker: Treatment sequencing in metastatic colorectal cancer. (Pubmed Central) - May 23, 2020
Immunotherapy with pembrolizumab or nivolumab ± ipilimumab may be considered for patients with high microsatellite instability disease...Ongoing trials are investigating the optimal sequencing and timing of therapies for mCRC. Molecular profiling has established new targets, and increasing knowledge of tumour evolution under drug pressure will possibly impact on sequencing.
- |||||||||| oxaliplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Oxaliplatin Plus Cetuximab: Are Uncertainties Unequivocally Settled? (Pubmed Central) - May 23, 2020 This combination of techniques requires a lower number of animals to obtain significant data and can accelerate the design of novel tracers. No abstract available
|